Therapeutic and diagnostic methods using total leukocyte surface

Details Therapeutic and diagnostic methods using total leukocyte surface Therapeutic and diagnostic methods using total leukocyte surface

1993-05-06

1996-06-11

Nucker, Christine M.

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

435 71, 435 72, 435 721, 435 722, 435 723, 435 724, 435 792, 435 793, 435 794, 435 795, 435974, 435975, G01N 3353

Patent

active

055254616

DESCRIPTION:

BRIEF SUMMARY
1. INTRODUCTION

The present invention is directed to the measurement of total leukocyte surface antigens, such as T cell receptors and T cell differentiation antigens or fragments thereof, and the application of such measurements in the diagnosis and therapy of diseases and disorders. The present invention is also directed to the measurement of soluble leukocyte antigens or fragments thereof, in conjunction with the measurement of total leukocyte surface antigens and the application of such dual measurements in the diagnosis and therapy of diseases and disorders. The measurement of such molecules, and preferably a plurality of such molecules, can be used in monitoring the effect of a therapeutic treatment, detecting and/or diagnosing disease.


2. BACKGROUND OF THE INVENTION



2.1. LEUKOCYTE SURFACE MOLECULES

Clusters of differentiation (CD) have been established which define human leukocyte differentiation antigens (Bernard and Boumsell, 1984, Hum. Immunol. 11:1-10; Knapp et al., 1989, Immunol. Today 10:253:258; Gebel et al., 1988, ASHI Quarterly 12:11; Leukocyte Typing III: White Cell Differentiation Antigens. Ed., McMichael, A. J. 1987. Oxford University Press. Oxford), by the comparison of reactivities of monoclonal antibodies directed against the differentiation antigens. The T cell surface antigens, their classification into epitope-defined subgroups, and their distributions on T cells have been studied by use of monoclonal antibodies directed against human T cells (Clark et al., 1983, Immunogenetics 18:599-615; Hansen et al., 1984, in Leucocyte Typing, Bernard, A., et al., eds., Springer-Verlag, New York, pp. 195-212). Some of the T cell clusters of differentiation and other cell surface molecules are listed in Table I.
These cell surface markers serve as markers of cell lineage, the identity of the functional T cell subset to which the T cell belongs, and the activation state of the T cell. Several of the cell surface molecules have been studied in great detail, have been found to be important in initiating and regulating immune functions and are critical to communication processes between immune cells.


TABLE I ______________________________________ LEUKOCYTE SURFACE MOLECULES Cell Detection Surface Monoclonal Refer- Marker Expression Antibodies ences ______________________________________ T cell Antigen All T cells and T40/25, 1, 2, 3, 4, Receptor T cell subsets .alpha.F1, .beta.F1, 5, 6 .delta.TCS1, TCR.delta.1,C.gamma.M1 CD1 Thymocytes & OKT6 Langerhans NAI/34 Calls, Lukemia Cells NK cell NK cells NC-37 7 receptor specific antibodies Cell Adhesion Molecules CD2 All T cells OKT11 8, 9, 10 Leu5 B67.1 CD58 (LFA-3) Leukocytes, TS2/9 11 epithelial CD3 Pan T cell OKT3 12 Leu4 CD4 Helper/Inducer OKT4 12 Subsets of T Leu3a cells CD5 T.B subsets UCHT2 11 T1 CD7 T Cells 3Al 11 CD8 Supressor/ .alpha. Chain: 13, 14 Cytotoxic OKT8 Subsets of T Leu2a cells .beta. Chain: 14a T8/2T8 .beta.2 integrins LeuCAM leukocyte cell 11 adhesion molecules CD11a (LFA-1) myeloid, 11, 15 lymphoid CD11b myeloid 11, 15, (MAC-1 (CR3)) 16, 17, 18, 19 CD11c (CR4) myeloid 11, 15 CD16 (FcR111) Natural Killer, HUNK2 11 Macrophages 3G8 Granulocytes CD21 (CR2) B subset B2 11, 20 HB5 CD23 (FC.epsilon.R11) B subset MHM6 11 Blast-2 CD25 TAC IL-2 Anti-TAC 21 Receptor 7G7/B6 (Activated T Cells) CD30 Activated T, B Ki-1 11 Cells HSR4 Reed-Steinberg Cells CD35 (CR1) Granulocytes, B YZ-1 11, 22 cells, monocytes J3D3 .beta.3 integrins CD41 11, 23 CD51 11, 23 Homing Leukocytes, 33-3B3 24 Receptors brain GRHL1 25, 26 CD44 Mel-14 .beta.1 integrins CD49a-f(VLA-1) Extra cellular 27, 23 VLA-2, VLA-3, Matrix (ECM) VLA-4 CD56 Natural Killer NKH1 11 (NKH1, NCAM) Activated Leu19 lymphocytes CD71 Transferring 11, 28 Receptor, Proliferating cells ______________________________________ List of References for Table I 1 Brenner et al., 1984, J. Exp.

REFERENCES:
patent: 4707443 (1987-11-01), Nelson et al.
patent: 5059524 (1991-10-01), McKennie et al.
patent: 5100777 (1992-03-01), Chang
patent: 5176998 (1993-01-01), McMillan
Ruppert, et al. "IL-4 Decreases the Expression of the Monocyte Differentiation Marker CD14, Paralleled by an Increasing Accessory Potency", Immunobiol. 182:449-464 (1991).
Prince, et al. "Depressed Interleukin 2 Receptor Expression in Acquired Immune Deficiency and Lymphadenopathy Syndromes", J. Immunol. 133:1313-1317 (1984).
Robbins, et al., "Immune Recognition of HLA Molecules Downmodulates CD8 Expression on Cytotoxic T Lymphocytes", J. Exp. Med. 173:221-230 (1991).
Endl et al., "A New ELISA-Based Assay for Quantitation of Human T-Lymphocyte Subpopulations", J. Immunol. Meth. 102:77-83 (1987).
Hessian, et al., "Development of an Enzyme Immunoassay for the Quantitation of Cellular Antigen Expression":, J. Immunol. Meth. 91:29-34 (1986).
Morris, et al., "Cellular Enzyme-Linked Immunospecific Assay (CELISA)--A New Micromethod that Detects Antibodies to Cell-Surface Antigens", Human Immunol. 5:1-19 (1982).
De Moyos et al., FASEB Abstract Form Received at Society Office by Tuesday, Dec. 8, 1987.
Rao et al., Cell Immunol. 80:310, (1983).
5929-933-225 PCT Publication No. 4,845,026 published Jul. 4, 1989.
Knowles et al., USA, 4,645,738, (Feb. 24, 1987).
Baldwin et al., Monoclonal Antibodies for Cancer Detection and Therapy, p. 20, Karl Erik Hellstrom and Hellstron, (1985).
Litman et al., U.S. patent No. 4,391,904, (Jul. 5, 1983).
Litman et al., U.S. patent No. 4,299,916, (Nov. 10, 1981).
David et al., U.S. patent No. 4,376,110 (Mar. 8, 1983).

Affiliated with

Also associated with

Rating

Therapeutic and diagnostic methods using total leukocyte surface does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic and diagnostic methods using total leukocyte surface, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic methods using total leukocyte surface will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-350858